泰格医药 港股通 空最新增减持 (2026-05-28) 官网 ( 03347.hk) | 31.51 | 1.15 | 0.45% (0.44%) | 上市时间2020-08-07股价31.70港币涨跌幅-0.69%成交金额6,343.80万港币换手率0.23%市值272.95亿港币H股市值39.03亿港币总股本8.61亿H股本1.23亿每手股数100上市至今年化投资收益率-18.72%港股通持仓占H股比例40.50% (16.19亿港币2026-06-03) 累计做空占H股比例9.22% (3.51亿港币2026-05-29) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 97.58 | 市净率 | 3.79 | 股息率 | 0.44% (0.30%) | 恒生:医疗保健业药品及生物科技生物技术 |
| 所属指数指数纳入纳出 | |||||||
| 同股同权 | 查看历史折扣 | ||||||
| 备注 (3): | 双击编辑备注 |
泰格医药(03347) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 聞增玉 | Executive Director | 2023-05-23 | -- | |
| 2 | 袁華剛 | Independent Non Executive Director | 2023-05-23 | -- | |
| 3 | 吳灝 | Executive Director | 2021-10-15 | -- | |
| 4 | 廖啟宇 | Independent Non Executive Director - A/F | 2020-04-01 | -- | |
| 5 | 楊波 | Independent Non Executive Director | 2020-04-01 | -- | |
| 6 | 鄭碧筠 | Independent Non Executive Director | 2017-06-01 | 2023-05-23 | |
| 7 | 曹曉春 | Executive Director | 2010-09-01 | -- | |
| 8 | 葉小平 | Executive Director | Chairman | 2010-09-01 | -- |
| 9 | YIN Zhuan | Executive Director | 2010-09-01 | 2023-05-23 |